◆ Contrarian Corpus
Corpus / Pershing Square → Valeant Pharmaceuticals International, Inc.
activist press release follow up
2016-04-25 · 1 pages

Valeant Pharmaceuticals International, Inc. VRX

N 1 Narrative
V 1 Visual
C 1 Craft
Unlock to download PDF Pershing Square archive ↗

Pattern membership

Where this document fits across the library's 12 rhetorical / structural patterns. Orange cells are present in this deck; neutral cells are not.

Villain named CEO-quote contradiction Before / after framing Peer-gap chart Sum of parts Fraud exposé Break-up / spinoff Governance / board Management change Proxy fight Top visual craft Masterclass

Slide gallery ·

No slide inventory yet

Pass-2 extraction may still be in progress for this deck.

Notes

Single-page administrative press release dated 25 April 2016 from Pershing Square IR (Amsterdam) forwarding Valeant's announcement that Joseph C. Papa was appointed Chairman and CEO. No thesis, no argumentation, no quantification — purely a procedural notification pointing investors to Valeant's own press release. Signed generically by 'Pershing Square IR' (ir@persq.com) rather than Ackman. Part of the ongoing Valeant campaign (Pearson-to-Papa succession) but contains no stand-alone investment case.

More on Valeant Pharmaceuticals International, Inc.

Pershing Square Mar 21, 2016

Valeant Pharmaceuticals International, Inc. VRX

N1 V1 C1
Pershing Square Mar 21, 2016

Valeant Pharmaceuticals International, Inc. VRX

N1 V1 C1

More from Pershing Square

Pershing Square Jan 16, 2025

Fannie Mae and Freddie Mac FNMA/FMCC

Fannie and Freddie have already repaid Treasury at an 11.6% IRR; releasing them from conservatorship via modest IPOs unlocks ~$300bn of warrant value for taxpayers within two years.

N5 V4 C4
⌂ ⇌
Pershing Square Jan 16, 2025

Fannie Mae / Freddie Mac FNMA / FMCC

Release Fannie and Freddie from conservatorship at a 2.5% capital standard and IPO them at ~$30+/share; Treasury's warrants generate ~$300bn while shares re-rate 5-6x from ~$6 today.

N5 V4 C4
⌂ ⇌ ⚑
Pershing Square Aug 17, 2017

Automatic Data Processing, Inc. ADP

ADP is a sleeping giant earning 19% Employer Services margins versus peers' 35-40% potential; electing Pershing's nominees catalyzes a transformation worth 100%+ in under four years.

N5 V4 C4
⌂ ◫ ” ⇌ ⚑
Pershing Square May 08, 2017

Howard Hughes Corporation HHC

HHC is the public-market way to invest alongside a Donald-Bren-style MPC compounder: irreplaceable master-planned communities with 37M SF of remaining entitlements, roughly 10x what's already built.

N5 V4 C4
⌂ ⇌
Pershing Square Jul 20, 2016

Herbalife HLF

The FTC's July 2016 Herbalife complaint and forced restructuring vindicate Pershing's pyramid-scheme short thesis; normalized EPS collapses to $1.42–$2.22, far below the ~$65 share price.

N5 V3 C3
” ⇌ ⚑
Pershing Square Oct 30, 2015

Valeant Pharmaceuticals International VRX

Citron's 'next Enron' attack on Valeant is a 1963 AmEx Salad Oil rerun — Philidor is ~7% of sales, the franchise is intact, and VRX at 7x cash EPS offers 60-215% upside.

N5 V3 C3
” ⚑